Recurrent glioblastoma, Lomustin – pro
Lomustine is an effecitve drug for glioblastoma. A prospective phase III trial in 92 lomustine treated patients (70 at first relapse) reported a 19% PFS6 response rate, with a median OS of 7.1 months.[42] In a double-blind, randomized, multicenter phase III trial of 325 patients who received prior radiation and TMZ, the lomustine monotherapy arm (n ¼ 65) provided PFS6 and median OS of 24.5% and 9.8 months. Lomustine is indicated for brain tumors – both primary and metastatic, in patients who have already received appropriate surgical and/or radiotherapeutic procedures.
1. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M
J Clin Oncol. 2013 Sep 10; 31(26):3212-8..
2. Heiland DH et al, Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine. J Neurooncol. 2016 Feb;126(3):567-75.
3. Lomustine Prescribing Information 2017
4. Sanjoy Roy, Debarshi Lahiri, Tapas Maji, and Jaydip Biswas, Recurrent Glioblastoma: Where we stand. South Asian J Cancer. 2015 Oct-Dec; 4(4): 163173.
5.NCCN, CNS, BRAIN-D, 2017